Professor. Division of Oncology, Departments of Medicine and Pathology; Director, Translational Research and Applied Medicine; Director of Research, Division of Oncology;
Associate Director, Director of Admissions, Medical Scientist Training Program (MSTP); Co-Director,
Translational Cancer Nanotechnology
Training Program; Stanford University School of Medicine
Elected Member, Association of American Physicians
Dr. Ge is CEO & President of Apostle. He has held leadership roles and management experience in both U.S.
and China companies. Previously, he was President of BioSciKin Co. and Simcere Diagnostics Co., two
global biotechnology companies headquartered in Nanjing, China focusing on the licensing and sales of
diagnostic technologies. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences,
where he founded the bioinformatics group and provided the strategic input to the bioinformatics
infrastructure and process. At Gilead, Dr. Ge and his group led the phylogenomic analytical support for
the critical regulatory approval of Sovaldi®, a world-leading anti-HCV drug. In 2014 and 2015, Dr. Ge
was invited to be a member of the U.S. National Human Genome Research Institute Special Emphasis Panel.
Prior to Gilead, he was appointed as Assistant Professor of Biostatistics and Bioinformatics and
Assistant Professor in Medicine at Duke University School of Medicine. He received his Ph.D. of
Biostatistics and Genetic Epidemiology in 2004 from Peking Union Medical College and Chinese Academy of
Medical Sciences, among the most selective medical colleges in the People's Republic of China, located in
Dr. Ge's work in discovering the IL28B genetic variants associated with the clinical treatment
responses, published in Nature in 2009, has received over 3000 times of citations to date. The invention
was licensed to LabCorp and Quest Diagnostics, and has become clinical diagnostic services since then
(LabCorp 480630 and Quest AccuType IL28). The U.S. FDA has cited this ground-breaking discovery in
several of the agency's guidance for industry. Dr. Ge has authored or co-authored over 70 peer-reviewed
articles, among which are 5 articles in Nature and 1 in Science, in total receiving over 19,000
Dr. Ge was named by the U.S. Genome Technology magazine as one of the "Rising Stars" in 2009, and
by the U.K. Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015.
Dr. Ge is a U.S. Citizen through the federal "Outstanding Professors and Researchers".
Bo Zhang, PhD.VP of Chemistry
Dr. Zhang received his Ph.D. of Chemistry from Stanford University in 2015 and received his B.S. of
Chemistry from Peking University in 2010. Dr. Zhang has won the gold medal of National Chemistry Olympiad
of China in 2006. Dr. Zhang has 10 years of experience in nanotechnology and biotechnology research. He
has made outstanding achievements in the field of fluorescence enhancing plasmonic gold nanomaterials, as
well as nanomaterials with fluorescence emission in the near infrared region. Fluorescence technology
plays critical role in modern biotechnology, especially in in vitro diagnostics and in vivo imaging. Dr.
Zhang published over 30 original research papers on top research journals (such as Nature Medicine,
Nature Materials, Nature Photonics, Nature Communications). Dr. Zhang's first author publication in
Nature Medicine about his work on novel diagnostic tools for type 1 diabetes has attracted worldwide
attention. Recently, Dr. Zhang has developed a nano platform for the sensitive and specific diagnosis of
Zika virus infection. The work was also published on Nature Medicine with Dr. Zhang as the first and
corresponding author, which delivered broad impact on the field of Zika diagnosis. Dr. Zhang has served
as principal investigator for research projects funded by the NIH, BioX, etc.
Dr. Zhang holds two
international patents, two US patents and one Chines patent. Dr. Zhang was the recipient of Materials
Research Society Graduate Student Awards, Mona M. Burgess SIGF Fellow, William S. Johnson Fellowship,
Fellowship for Chinese Student Study Abroad, etc.
Forbes China named Dr. Zhang as one of the most
brilliant young entrepreneurs under 30 in its annual "30 under 30" list of 2017.
Xin Guo, PhD.VP of Bioinformatics
Dr. Guo was research scientist and research group lead at Gilead Sciences, Inc., a world leading
biotechnology company specialized in hepatitis C and HIV medication. Dr. Guo was in charge of the
clinical phylogenomic program for the clinical development of Sovaldi®, a world-leading anti-HCV
drug. Dr. Guo received his Ph.D. in Computer Sciences from Duke University, M.S. in Informatics from Max
Planck Institute of Germany and B.S. from Japan.
Dr. Guo has over 10 years of experience in the
research and development of high performance computing, machine learning and artificial intelligence. Dr.
Guo has extensive experience in the product development of complex big data algorithms and databases,
with applications in bioinformatics and genomic big data. He has led multiple publications in AI,
including an influential first-author research article in PNAS.
Eric D. MasingaleVP of Business Operations
Eric D. Masingale is VP of Business Operations at Apostle Inc. Mr. Masingale has over 20 years of experience in sales
in the medical device industry, and is a global executive and enterprising business leader with a successful track record including:
Co-led transformation of medtech R&D company from 510(k) approval of a proprietary surgical device/procedure to a market-focused growth strategy that produced $14M in annual revenue (without reimbursement) in 13 months. Created business and sales/marketing structure, developed brand, built team, and played a key role in positioning business for sale to J&J.
Member of global executive leadership team that drove 10-fold expansion of medical medtech business to $1B+ annual revenue. Leading a sales and marketing organization across the Americas, APAC, and EMEA, met/exceeded double-digit quarterly and annual quota/growth targets for 24+ months.
Recruited back to deliver transformation of underperforming, 20-state western district representing 20% of division’s total annual revenue. Increased sales 25%+ to $317M+ over 3 years in the midst of continuous shifts in executive management.
Ushered endoscopy marketing organization into a new era of alignment with global sales force. As a result, marketing and sales efforts produced $275M revenue increase to $650M in 2 years, the same growth division had seen in prior 10 years.
Effectively navigated sales/operations teams through acquisitions/mergers, leadership gaps/transitions, market downturns, territory restructurings, shifts in corporate strategy, and the introduction of innovative products and technologies.
Selected by Group President to lead development and oversight of marketing leadership council and biannual conference that promoted the sharing of best practices across the entire global organization. Model is still in place after 12 years.
Featured speaker for various company and industry events in the areas of leadership, sales operations, and innovation.
Played a key role in development of UC San Diego School of Medicine’s Center for the Future of Surgery.
Recruited, cultivated, and advanced top talent, many of whom are now in executive-level roles across the industry (including a Group President for a Fortune 500 medical device company).
Prior to joining Apostle, Mr. Masingale held leadership roles in sales and marketing in various medical device companies, including Stryker,
Torax Medical (acquired by J&J), and Reps Scrubs. He was Global VP of Sales and Marketing of Stryker Endoscopy between 2006 and 2012, and
Global VP of Sales and Marketing of Torax Medicial between 2012 and 2014.
Mr. Masingale held B.A. of Speech Communications from California State University Hayward, and joined Executive Leadership Program of Harvard Business School in 2010 and 2013.
Wenqi Zeng, MD. PhD. FACMG.Chief Medical Advisor
Dr. Zeng is Chief Medical Officer of Simcere Diagnostics Co. Before Apostle and Simcere, Dr. Zeng was
Senior Director of Molecular Genetics at Quest Diagnostics and was Director of Clinical Genomics at Ambry
Genetics. Prior to Ambry, he was co-Director of Clinical Molecular Genetics at City of Hope National
Medical Center. Dr. Zeng was fellow of Clinical Molecular Genetics and Human/Medical Genetics at Harvard
University. He Received his M.D. from Xiang-Ya Medical School, Central South University in China and
Ph.D. in Molecular Patholgy/Molecular Genetics from University of Otago.
He holds Diploma of
American Board of Medical Genetics and Genomics (ABMGG), and is a qualified CAP inspection team leader,
and a qualified CAP CLIA lab director in CA, FL and MD. He also has New York state COQ in molecular
genetics and molecular oncology.
William Dai, MBADirector
Founding Partner, ShangBay Capital
CFO, ShangPharma Corporation (NYSE:SHP)
CFO, China Nepstar Corporation (NYSE: NPD), the largest chain drugstore in China
CFO and Vice Chair of the Executive Committee, Microport Scientific Corporation (HK: 00853)
CFO China, Boston Scientific Corporation (NYSE: BSX), one of the largest invasive medical
device company in the world
Ford Motor Company – Finance Manager at Treasury, World Headquarters in Michigan
MBA, Michigan State University
William Dai has more than 20 years of experience in corporate finance, mergers and acquisitions, and
capital markets in both China and the U.S. He has held senior executive roles at major U.S. multinational
In those roles, William was responsible for overall execution and was held accountable to the highest
ethical standards in his business dealings.
He is well-respected among financial and investment circles, and is a recognized leader in the
In addition, due to his hands-on experience leading multiple large international medical device
companies, he has a very in-depth knowledge of the medical device industry and its market dynamics.
William Dai holds a master’s degree in business administration with an emphasis on finance from Michigan
Shuting Zhao, PhDSenior Scientist
Dr. Zhao received her Ph.D. in Biomedical Engineering from Ohio State University in 2016, M.S. from
Cornell University, and B.S. from Zhejiang University in China. Dr. Zhao has over 5 years research
experience in micro and nano scale biomaterials and their applications on regenerative medicine, cancer
treatment, drug delivery and drug screening, with 19 co-authored peer-reviewed publications in top
journals and one US patent. Dr. Zhao was also an HHMI Med into Grad scholar in Ross Heart Hospital and
has industrial experience from Vertex Pharmaceuticals.
Joshua Robinson, PhDPrincipal Business Development Consultant
Dr. Joshua Robinson is an Innovation Leader at Clorox, a Fortune 500 Consumer Packaged Goods company.
Prior to this, he was a founding team member and the Director of R&D at Nirmidas Biotech, Inc., a
point-of-care diagnostic company spun out of Stanford University in 2013. Dr. Robinson helped Nirmidas
begin operations out of QB3@953, a life science incubator space in San Francisco, as a Janssen Labs
sponsored company. While at Nirmidas, he worked to secure $2 million in seed funding and $5 million in
Series A funding, file multiple patents, and win an SBIR award.
Before helping to found Nirmidas, Dr. Robinson was a senior application scientist at Beckman
Coulter, Inc., focused on particle characterization devices. Josh holds a Ph.D. in physical chemistry
from Stanford University working under Prof. Hongjie Dai. His graduate research, which focused developing
biocompatible graphene and other nanomaterials for in vivo cancer diagnostics and therapy, helped
establish the field of graphene medicine and resulted in over 2 dozen publications that have been cited
over 12,000 times.